Physician-researcher receives 2012 Alliance Research Grant
VCU Massey Cancer Center hematologist-oncologist Beata Holkova, M.D., was recently awarded an Alliance Research Grant to support her work involving drug combinations to battle B-cell lymphomas. The grant was presented at this year’s Alliance Group Meeting in Chicago, Illinois. Holkova is a Harrison Endowed Scholar and member of the Developmental Therapeutics research program at VCU Massey Cancer Center and assistant professor of hematology-oncology and internal medicine at the VCU School of Medicine.
Viagra drug trio improves effectiveness of cancer treatment while protecting the heart
A new drug combination featuring the widely-known impotence drug Viagra has been found to improve the effectiveness of cancer treatment while protecting the heart from harm caused by a popular form of chemotherapy. With nearly half of all cancer survivors dying from other conditions than cancer, most notably cardiovascular disease, this new treatment is not only innovative but necessary.
Massey leader Harry Bear appointed to prestigious board
VCU Massey Cancer Center leader and physician-researcher Harry Bear, M.D., Ph.D., has been appointed to serve on the Board of Directors of the NSABP Foundation, Inc. The NSABP – National Surgical Adjuvant Breast and Bowel Project – Foundation is the world’s leading cooperative group for designing and conducting large-scale breast and colorectal cancer clinical trials. Supported by the National Cancer Institute (NCI) since its inception more than 50 years ago, the group has pioneered trials that have changed the way breast and bowel cancers are treated and prevented.
The Promise of Immunotherapy
Recently, the American Association for Cancer Research partnered with Time magazine, the Mayo Clinic Cancer Center and the Cancer Research Institute for a Twitter chat on “The Promise of Immunotherapy.” VCU Massey Cancer Center oncologists and researchers, John McCarty, M.D., and Andrew Poklepovic, M.D., provided expert commentary as the moderators posed a series of questions and discussion topics.
Whole exome sequencing shows potential to improve efficacy of stem cell transplants
Stem cell transplant donors and recipients are matched using a process known as human leucocyte antigen (HLA) testing, but graft-versus-host disease (GVHD), in which the donor's immune system attacks the recipient’s body, continues to pose a significant threat to transplant patients. Now, researchers at Virginia Commonwealth University (VCU) Massey Cancer Center have sequenced the DNA of a small group of stem cell transplant recipients and their donors and discovered significant variation in their exomes that may help explain why some HLA-matched stem cell transplant recipients still suffer from GVHD.